Harmony Biosciences names Peter Anastasiou CEO, succeeding Jeffrey Dayno

Harmony Biosciences Holdings announced on October 12, 2026 that its board appointed Peter Anastasiou, currently Senior Executive Vice President and Chief Operating Officer, to become President, Chief Executive Officer and a board member effective January 1, 2027. The company said the appointment is part of the board's succession planning.¹

Current CEO Jeffrey M. Dayno, M.D. will retire at the end of the year following a nine-year tenure at the company, including as Chief Medical Officer, and step down as a member of the Board.¹ Dayno is set to serve as a non-executive advisor to the company through 2027 to support Harmony's growth objectives.¹

Alongside the leadership news, Harmony reiterated full-year 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion and said it remains on track to report data from the multiple ascending dose study of BP-205 in the fourth quarter of 2026.¹

According to the filing, Anastasiou, age 55, has served as Harmony's Chief Operating Officer since April 2026, was CEO and a board member of Capsida Biotherapeutics, described in the filing as a next-generation integrated gene therapy company, from January 2022 to October 2025, and before that spent from November 2009 to December 2021 at Lundbeck in roles including Executive Vice President and President of North America.¹ He also previously served as a member of Harmony's board from November 2023 to April 2026.¹

The filing states there are no arrangements or understandings between Anastasiou and any other person related to his selection, no family relationships with any Harmony director or officer, and no reportable related-party transactions involving him, and he will not receive additional compensation for his board service.¹